JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

Journal of Investigative Dermatology

Volumn 136, Issue 6, 2016, Pages 1281-1283

  Wenzel, Joerg ^a   van Holt, Nadine ^a   Maier, Judith ^a   Vonnahme, Maria ^a   Bieber, Thomas ^a   Wolf, Dominik ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CALRETICULIN; JANUS KINASE INHIBITOR; MYXOVIRUS RESISTANCE PROTEIN A; PREDNISONE; RUXOLITINIB; JANUS KINASE 1; JANUS KINASE 2; PYRAZOLE DERIVATIVE; STAT PROTEIN;

ACUTE LIVER FAILURE; AGED; ARTICLE; AUTOINFLAMMATORY DISEASE; CASE REPORT; CHILBLAIN; CORTICOSTEROID THERAPY; DERMATITIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; EXON; FEMALE; FEVER; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; LUPUS ERYTHEMATOSUS; MYELOID METAPLASIA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; PHYSIOLOGY; SKIN LUPUS ERYTHEMATOSUS;

AGED; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; LUPUS ERYTHEMATOSUS, CUTANEOUS; PYRAZOLES; STAT TRANSCRIPTION FACTORS;

EID: 84978396778     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.02.015     Document Type: Article

References (16)

1. Chan, E.S., Herlitz, L.C., Jabbari, A., Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model. J Invest Dermatol 135 (2015), 1912–1915.
2. Craiglow, B.G., King, B.A., Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 151 (2015), 1110–1112.
3. Fridman, J.S., Scherle, P.A., Collins, R., Burn, T., Neilan, C.L., Hertel, D., et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 131 (2011), 1838–1844.
4. Guglielmelli, P., Rotunno, G., Bogani, C., Mannarelli, C., Giunti, L., Provenzano, A., et al. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis [e-pub ahead of print]. Br J Haematol, 2015 http://dx.doi.org/10.1111/bjh.13644 (accessed 30 August 2015).
5. Heine, A., Brossart, P., Wolf, D., Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood 122 (2013), 3843–3844.
6. Hornung, T., Janzen, V., Heidgen, F.J., Wolf, D., Bieber, T., Wenzel, J., Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371 (2014), 2537–2538.
7. Hornung, T., Wolf, D., Wenzel, J., More on remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med, 372, 2015, 1274.
8. Jabbari, A., Dai, Z., Xing, L., Cerise, J.E., Ramot, Y., Berkun, Y., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2 (2015), 351–355.
9. Levy, L.L., Urban, J., King, B.A., Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73 (2015), 395–399.
10. Parampalli Yajnanarayana, S., Stubig, T., Cornez, I., Alchalby, H., Schonberg, K., Rudolph, J., et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol 169 (2015), 824–833.
11. Punwani, N., Scherle, P., Flores, R., Shi, J., Liang, J., Yeleswaram, S., et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 67 (2012), 658–664.
12. Santos, F.P., Verstovsek, S., JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?. Anticancer Agents Med Chem 12 (2012), 1098–1109.
13. Schonberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75 (2015), 2187–2199.
14. Scofield, R.H., Racila, D.M., Gordon, T.P., Kurien, B.T., Sontheimer, R.D., Anti-calreticulin segregates anti-Ro sera in systemic lupus erythematosus: anti-calreticulin is present in sera with anti-Ro alone but not in anti-Ro sera with anti-La or anti-ribonucleoprotein. J Rheumatol 27 (2000), 128–134.
15. Xing, L., Dai, Z., Jabbari, A., Cerise, J.E., Higgins, C.A., Gong, W., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20 (2014), 1043–1049.
16. Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S.K., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29 (2015), 2062–2068.